South Dakota Investment Council Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

South Dakota Investment Council purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,529 shares of the medical research company’s stock, valued at approximately $2,462,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in IQVIA during the third quarter worth about $27,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC purchased a new stake in IQVIA during the fourth quarter worth about $33,000. Assetmark Inc. increased its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Concord Wealth Partners purchased a new stake in IQVIA during the third quarter worth about $57,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $190.94 on Monday. The company has a market capitalization of $33.62 billion, a P/E ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The business has a 50 day simple moving average of $199.57 and a 200-day simple moving average of $216.25. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on IQV shares. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Barclays cut their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.